Santen Pharmaceutical Co., Ltd. (4536.T) JPX

Currency In JPY

Key Executives

Name	Title	Pay	Year Born
Takeshi Ito	President, Chief Executive Officer & Representative Director	172M	1959
Rie Nakajima	Chief Operating Officer, Corporate Officer & Director	0	1977
Yoko Saiki	Corporate Officer & Chief Human Resources Officer	0	N/A
Kenji Morishima	Corporate Officer & Head of China Product Development Department	0	N/A
Shinichi Teramachi	Corporation Officer, Head of Sales and Head of Japan Sales & Marketing	0	N/A
Takahiro Morita	Global Head of Core Principle & Sustainability and Corporate Officer	0	N/A
Daisuke Nakata	Chief Digital & Information Officer	0	N/A
Kaori Itagaki	General Manager of Investor Relations Group	0	N/A
Mika Masunari	Corporate Officer, General Counsel, Chief Risk Officer & Chief Compliance Officer	0	N/A
Kazuo Koshiji	Chief Financial Officer & Corporate Officer	0	N/A

Name

Title

Pay

Year Born

Takeshi Ito

President, Chief Executive Officer & Representative Director

172M

1959

Rie Nakajima

Chief Operating Officer, Corporate Officer & Director

1977

Yoko Saiki

Corporate Officer & Chief Human Resources Officer

N/A

Kenji Morishima

Corporate Officer & Head of China Product Development Department

N/A

Shinichi Teramachi

Corporation Officer, Head of Sales and Head of Japan Sales & Marketing

N/A

Takahiro Morita

Global Head of Core Principle & Sustainability and Corporate Officer

N/A

Daisuke Nakata

Chief Digital & Information Officer

N/A

Kaori Itagaki

General Manager of Investor Relations Group

N/A

Mika Masunari

Corporate Officer, General Counsel, Chief Risk Officer & Chief Compliance Officer

N/A

Kazuo Koshiji

Chief Financial Officer & Corporate Officer

N/A

Description

Santen Pharmaceutical Co., Ltd. is a global enterprise engaged in the research, development, manufacturing, and marketing of both pharmaceutical products and medical devices. The company's primary focus lies in ophthalmic solutions, addressing a variety of eye conditions. Its pipeline for glaucoma and ocular hypertension includes several key assets: DE-111, currently in Phase III clinical trials; DE-117, available for sale in Japan; DE-126, progressing through Phase IIb trials; DE-128, which is on the market in Europe and undergoing Phase II/III trials in the United States; and DE-130A, also in Phase III development. Beyond glaucoma, Santen's offerings extend to other ocular ailments. It provides DE-114A for allergic conjunctivitis and DE-076C for vernal keratoconjunctivitis. Furthermore, DE-109 is in Phase III clinical trials for the treatment of uveitis. The company is also active in addressing myopia with DE-127, currently in Phase II/III trials in Japan and Phase III in other Asian markets, alongside STN1013400, which is in Phase I trials. For dry eye, Santen offers DE-089C, which has successfully concluded its Phase III clinical trials. In addition to its prescription portfolio, the company produces and sells various over-the-counter (OTC) pharmaceutical products. Founded in 1890 under the name Santendo Pharmaceutical Co., Ltd., the company rebranded to its current name, Santen Pharmaceutical Co., Ltd., in 1958. It is headquartered in Osaka, Japan.